慢加急性肝衰竭并发急性肾损伤诊疗进展*

doi:10.3969/j.issn.1672-5069.2025.05.040

摘要/Abstract

摘要： 慢加急性肝衰竭(ACLF)是肝脏合成、解毒、代谢和转化功能严重障碍后出现的临床症候群,可并发多脏器衰竭,病死率高。肝肾综合征(HRS)是ACLF的严重并发症之一,是急性肾损伤(AKI)的特殊形式,是影响ACLF患者预后的独立危险因素。早期发现AKI并及时处理可有效降低ACLF患者的病死率。

关键词: 慢加急性肝衰竭, 急性肾损伤, 肝肾综合征

Abstract: Objective Acute-on-chronic liver failure (ACLF) is a clinical syndrome that occurs after severe impairment of hepatic synthesis, detoxification, metabolism, and transformation functions, and can be complicated by multiple organ failure with a high morbidity and mortality rate. Hepatorenal syndrome (HRS) is one of the serious complications of ACLF, which is a special form of acute kidney injury (AKI) and an independent risk factor affecting the prognosis of patients with ACLF, and early diagnosis and treatment of AKI might effectively improve the prognosis of patients with ACLF.

Key words: Acute-on-chronic liver failure, Acute kidney injury, Hepatorenal syndrome

杜冰玉, 李俊峰, 张立婷. 慢加急性肝衰竭并发急性肾损伤诊疗进展^*[J]. 实用肝脏病杂志, 2025, 28(5): 797-800.

Du Bingyu, Li Junfeng, Zhang Liting. Early diagnosis and treatment of patients with acute-on-chronic liver failure complicated with acute kidney injury[J]. Journal of Practical Hepatology, 2025, 28(5): 797-800.

参考文献

[1] Bajaj JS, O'leary JG, Lai JC, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol,2022,117(2):225-252.
[2] Angeli P, Ginès P, Wong F, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut,2015,64(4):531-537.
[3] Jiang W, Hu Y, Sun Y, et al. Prevalence and short-term outcome of acute kidney injury in patients with acute-on-chronic liver failure: A meta-analysis. J Viral Hepat,2020,27(8):810-817.
[4] Trebicka J, Fernandez J, Papp M, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. J Hepatol,2020,73(4):842-854.
[5] Zhao RH, Shi Y, Zhao H, et al. Acute-on-chronic liver failure in chronic hepatitis B: an update. Expert Rev Gastroenterol Hepatol,2018,12(4):341-350.
[6] Yang J, Nie QH, Wang AH, et al. Effects of intestinal intervention on bacterial translocation in a rat model of acute liver failure in vivo. Eur J Gastroenterol Hepatol,2010,22(11):1316-1322.
[7] Wang XL, Chen XJ, Ye HH, et al. Association of mRNA expression level of IP-10 in peripheral blood mononuclear cells with HBV-associated acute-on-chronic liver failure and its prognosis. J Huazhong Univ Sci Technolog Med Sci,2017,37(5):755-760.
[8] Solé C, Sola E, Huelin P, et al. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver Int,2019,39(7):1246-1255.
[9] Lu J, Lin L, Ye C, et al. Serum NGAL is superior to cystatin C in predicting the prognosis of acute-on-chronic liver tailure. Ann Hepatol,2019,18(1):155-164.
[10] Grønbaek H, Møller HJ, Saliba F, et al. Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute-on-chronic liver failure and acute decompensation. J Gastroenterol Hepatol,2021,36(1):240-248.
[11] Solé C, Guilly S, Da Silva K, et al. Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis. Gastroenterology,2021,160(1):206-218.
[12] Zhang Y, Zhao R, Shi D, et al. Characterization of the circulating microbiome in acute-on-chronic liver failure associated with hepatitis B. Liver Int,2019,39(7):1207-1216.
[13] Ponziani FR, Zocco MA, Cerrito L, et al. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Rev Gastroenterol Hepatol,2018,12(7):641-656.
[14] Mathurin S, Chapelet A, Spanevello V, et al. Infections in hospitalized patients with cirrhosis. Medicina (B Aires),2009,69(2):229-238.
[15] Li C, Wang W, Xie SS, et al. The programmed cell death of macrophages, endothelial cells, and tubular epithelial cells in sepsis-AKI. Front Med,2021,8:796724.
[16] Krones E, Eller K, Pollheimer MJ, et al. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. J Hepatol,2017,67(1):110-119.
[17] Choy KW, Wijeratne N, Chiang C, et al. Copeptin as a surrogate marker for arginine vasopressin: analytical insights, current utility, and emerging applications. Crit Rev Clin Lab Sci,2024,31:1-21.
[18] Kerbert AJC, Verspaget HW, Navarro ÀA, et al. Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. Crit Care,2017,21(1):321.
[19] Piano S, Favaretto E, Tonon M, et al. Including relative adrenal insufficiency in definition and classification of acute-on-chronic liver failure. Clin Gastroenterol Hepatol,2020,18(5):1188-1196,e3.
[20] Davenport A, Sheikh MF, Lamb E, et al. Acute kidney injury in acute-on-chronic liver failure: where does hepatorenal syndrome fit? Kidney Int,2017,92(5):1058-1070.
[21] Markwardt D, Holdt L, Steib C, et al. Plasma cystatin C is a predictor of renal dysfunction, acute‐on‐chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology,2017,66(4):1232-1241.
[22] Gomez-casado C, Roth-walter F, Jensen-jarolim E, et al. Modeling iron-catecholates binding to NGAL protein. J Mol Graph Model,2013,45:111-121.
[23] Gambino C, Piano S, Stenico M, et al. Diagnostic and prognostic performance of urinary neutrophil gelatinase‐associated lipocalin in patients with cirrhosis and acute kidney injury. Hepatology,2023,77(5):1630-1638.
[24] Sabbisetti VS, Waikar SS, Antoine DJ, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol,2014,25(10):2177-2186.
[25] Vaidya VS, Ramire V, Ichimura T, et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol,2006,290(2):F517-F529.
[26] Acharya P, Saha R, Quadri JA, et al. Quantitative plasma proteomics identifies metallothioneins as a marker of acute-on-chronic liver failure associated acute kidney injury. Front Immunol,2023,13:1041230.
[27] Liu Y, Yuan W, Fang M, et al. Determination of HMGB1 in hepatitis B virus-related acute-on-chronic liver failure patients with acute kidney injury: Early prediction and prognostic implications. Front Pharmacol,2023,13:1031790.
[28] Susantitaphong P, Siribamrungwong M, Doi K, et al. Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis. Am J Kidney Dis,2013,61(3):430-439.
[29] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版). 中华肝脏病杂志,2019,27(1):9.
[30] Allegretti AS, Solà E, Ginès P, et al. Clinical application of kidney biomarkers in cirrhosis. Am J Kidney Dis,2020,76(5):710-719.
[31] Best LM, Freeman SC, Sutton AJ, et al. Treatment for hepatorenal syndrome in people with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev,2019,9(9):CD013103.
[32] Arora V, Maiwall R, Rajan V, et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology,2020,71(2):600-610.
[33] Angeli P, BernardI M, Villanueva C, et al. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol,2018,69(2):406-460.
[34] Sridharan K, Sivaramakrishnan G. Vasoactive agents for hepatorenal syndrome: a mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials. J Gen Intern Med,2018,33:97-102.
[35] Nazar A, Pereira GH, Guevara M, et al Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology,2010,51:219-226.
[36] Ding C, Wu X, Fan X, et al. Hemodynamic effects of continuous versus bolus infusion of terlipressin for portal hypertension: a randomized comparison. Gastroenterol. Hepatol,2013,28:1242-1246.
[37] Cavallin M, Piano S, Romano A,et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology,2016,63:983-992.
[38] Jindal A, Singh H, Kumar G, et al. Early versus standard initiation of terlipressin for acute kidney injury in ACLF: a randomized controlled trial (eTerli Study).Dig Dis Sci,2024,69(6):2204-2214.
[39] Weinberg JM. Lipotoxicity. Kidney Int,2006,70(9):1560-1566.
[40] Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet,2018,391(10138):2417-2429.
[41] China L, Freemantle N, Forrest E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med,2021,384(9):808-817.
[42] Sourianarayanane A, Raina R, Garg G, et al. Management and outcome in hepatorenal syndrome:need for renal replacement therapy in non-transplanted patients.Int Urol Nephrol,2014,46(4):793-800.
[43] Zhang Z, Maddukuri G, Jaipaul N, et al. Role of renal replacement therapy in patients with type 1 hepatorenal syndrome receiving combination treatment of vasoconstrictor plus albumin. J Crit Care,2015,30(5):969-974.
[44] Karvellas CJ, Taylor S, Bigam D, et al. Intraoperative continuous renal replacement therapy during liver transplantation: a pilot randomized-controlled trial (INCEPTION). Can J Anaesth,2019,66(10):1151-1161.
[45] Niewinski G, Raszeja-wyszomirska J, Hrenczuk M, et al. Intermittent high-flux albumin dialysis with continuous venovenous hemodialysis for acute-on-chronic liver failure and acute kidney injury. Artif Organs,2020,44(1):91-99.
[46] Weinberg EM, Wong F, Vargas HE, et al. Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin. Liver Transpl,2023,10:1097.
[47] Macdonald AJ, Nadim MK, Durand F, et al. Acute kidney injury in cirrhosis: implications for liver transplantation. Curr Opin Crit Care,2019,25(2):171-178.
[48] Yang H, Sun L, Pang Y, et al. Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure. Gut,2021,70(3):567-574.
[49] Pita A, Kaur N, Emamaullee J, et al. Outcomes of liver transplantation in patients on renal replacement therapy: considerations for simultaneous liver kidney transplantation versus safety net. Transplant Direct,2019,5(10):e490.
[50] Bera C, Wong F. Management of hepatorenal syndrome in liver cirrhosis: a recent update. Therap Adv Gastroenterol,2022,15: 17562848221102679.

慢加急性肝衰竭并发急性肾损伤诊疗进展^*

Early diagnosis and treatment of patients with acute-on-chronic liver failure complicated with acute kidney injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中华医学会肝病学分会重型肝病与人工肝学组, 中华医学会肝病学分会终末期肝病营养与再生学组. 慢加急性肝衰竭诊治指南(2025 年版)[J]. 实用肝脏病杂志, 2025, 28(5): 641-647.
[2]	李勇飞, 许正锯, 叶巧霞, 威晋. 血浆置换联合血液滤过治疗慢加急性乙型肝炎肝衰竭患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 394-397.
[3]	郭建晖, 周永兵, 何钦. 慢加急性乙型肝炎肝衰竭患者血清sST2、TLR4、suPAR和Beclin1水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(2): 230-233.
[4]	封顺, 赵磊, 张丽娟. 慢加急性肝衰竭患者血清人β防御素-1、高尔基体蛋白73和白介素-33水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(1): 80-83.
[5]	孙敏, 张倩, 徐刚, 王加林, 何振文. ACLF患者肺部感染发生率及预测因素分析^*[J]. 实用肝脏病杂志, 2025, 28(1): 84-87.
[6]	徐曼曼, 杨颜榕, 李珊珊, 武羽, 杨雪, 段钟平, 陈煜. 我院近10年肝衰竭患者预后变化趋势分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 874-877.
[7]	丘仲琼, 林建辉, 翁钘钘, 陈丽霞, 刘海钰. 影响慢加急性乙型肝炎肝衰竭并发医院获得性肺炎患者预后危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 878-881.
[8]	武羽, 韩宇星, 徐曼曼, 焦婧然, 杨雪, 段小宛, 陈煜. DRG付费改革背景下慢加急性肝衰竭患者费用盈亏分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 882-886.
[9]	董旭, 秦阳华, 廖威, 许明晓, 葛玲玲, 李成忠. 乙型肝炎肝硬化和慢加急性肝衰竭患者并发感染影响因素与预后分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 891-894.
[10]	黄静, 王菁, 方亮, 周娟, 商惠民. 血清wnt5a和LC3-Ⅱ联合MELD评分预测慢加急性乙型肝炎肝衰竭患者短期预后价值探讨^*[J]. 实用肝脏病杂志, 2024, 27(4): 551-554.
[11]	柯海霞, 张娇珍, 蒙夏玲, 许政衡, 邓丕豪. 慢加急性乙型肝炎肝衰竭患者血清CRP和sTREM-1水平变化及其预测继发感染的价值研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 555-558.
[12]	董旭, 秦阳华, 陈怡, 许明晓, 葛玲玲, 徐圣, 廖威. 预后营养指数联合全身免疫炎症指数评估乙型肝炎相关慢加急性肝衰竭患者预后临床价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 390-393.
[13]	刘松涛, 孟庆华, 刘梅, 韩亚男, 王金环, 闾军. 急性/亚急性肝衰竭患者急性肾损伤发生率和预后分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 222-225.
[14]	李菲, 陈辛未, 李琦. HBV相关慢加急性肝衰竭患者血清GP73、suPAR和AT-Ⅲ水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 847-850.
[15]	田宇, 陈燕, 曹佳非, 周晓倩. 肝硬化并发肝肾综合征患者U-mAl及外周血NLR和血清NGAL水平变化研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 859-862.